Hong Kong Logistics Stock News

Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed a HK$1.28b IPO in Hong Kong, an event that brings new attention to its kidney disease drug pipeline and newly listed H shares. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). The strong first day reception for Alebund Pharmaceuticals (Jiangsu) has been followed by a 1 day share price return of 18.75% to HK$30.28, although the share price return year to date is down 34.17%. This suggests short term momentum is...

COSCO SHIPPING Ports Limited ( HKG:1199 ), might not be a large cap stock, but it saw significant share price movement...

What changed at NetEase and why it matters for shareholders NetEase (SEHK:9999) recently approved a Third Amended and Restated Memorandum and Articles of Association at its 2026 Annual General Meeting, a governance update that helps frame how investors may view the stock’s latest move. The bylaw changes came shortly after NetEase stock gained 7.32% over the past week, following quarterly earnings of HK$4.03 per share versus an estimated HK$3.42, a 17.77% difference that has drawn fresh...

Legendary Education Group Limited's ( HKG:8195 ) recent earnings report didn't offer any surprises, with the shares...

Despite posting healthy earnings, China High Speed Transmission Equipment Group Co., Ltd.'s ( HKG:658 ) stock has been...

As you might know, China Water Affairs Group Limited ( HKG:855 ) recently reported its full-year numbers. Statutory...

It looks like China Taiping Insurance Holdings Company Limited ( HKG:966 ) is about to go ex-dividend in the next four...

GSMA membership and AI focused network upgrade reshape the China Tower story China Tower (SEHK:788) has joined the GSMA and completed a nationwide upgrade that turns 5.6 million base stations and 2.1 million tower sites into intelligent edge computing hubs for connectivity in the AI era. See our latest analysis for China Tower. Despite the AI focused upgrade and GSMA membership, China Tower’s recent share price momentum has softened, with the stock at HK$9.04 and the 1 month share price...

CITIC (SEHK:267) drew investor attention after its 26 June 2026 AGM, where the company declared a 2025 final dividend of RMB 0.385 per share, payable in either RMB or Hong Kong dollars. See our latest analysis for CITIC. While the 2025 final dividend announcement has focused attention on income, CITIC’s 1 month share price return is down 20.98% and the year to date share price return is down 13%, even as the 5 year total shareholder return of 83.56% points to a much stronger long term...

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...

Country Garden Holdings (SEHK:2007) has reported June contracted sales of about CN¥2.45b, down 13% year-on-year. The company also reported weaker first half sales and its first interest payment under a major offshore debt restructuring. See our latest analysis for Country Garden Holdings. The June sales update and progress on offshore debt restructuring come after a mixed price pattern for Country Garden Holdings, with the share price up 8.67% over one day and 10.59% over seven days, but down...

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...

In June 2026, Geely Automobile Holdings reported a 2% rise in total vehicle sales, powered by very large export growth and a 111% year-on-year jump in deliveries from its premium electric brand ZEEKR. This combination of stronger international demand and rapid electric vehicle momentum underscores how Geely is building a broader global footprint beyond its core China market. We’ll now explore how this surge in exports and ZEEKR’s rapid growth could influence Geely’s existing investment...

As global markets navigate mixed signals, with U.S. small-cap indices like the Russell 2000 experiencing declines and China's manufacturing sector showing resilience, investors are keenly observing Asia's evolving economic landscape. In this environment, identifying promising stocks often involves looking for companies that demonstrate strong fundamentals and adaptability to shifting market conditions.

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...

Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( HKG:1497 ), is not the largest company out there, but it saw a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Man Wah Holdings Limited ( HKG:1999 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date generally...

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.

It's been a mediocre week for Want Want China Holdings Limited ( HKG:151 ) shareholders, with the stock dropping 17% to...

Sino Biopharmaceutical (SEHK:1177) is back in focus after China’s regulators approved Peceleganan Spray and accepted a new drug application for tecotabart vedotin, LM-302. These are two pipeline milestones in infection control and advanced gastric cancer. See our latest analysis for Sino Biopharmaceutical. Despite the drug pipeline progress, Sino Biopharmaceutical’s share price tells a mixed story. The HK$4.62 close reflects a 1-day share price return of 4.76% and a 7-day gain of 8.45%, set...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn investor attention after new translational research on its sac-TMT and osimertinib combination for EGFR-mutant non small cell lung cancer was published in the journal Cancer Cell. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest Cancer Cell publication and wider sac-TMT trial updates arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$467.6, with a year to date share price return of 16.72%...

Baijin Life Science Holdings (SEHK:1466) has posted its latest full year update with first half FY 2026 revenue of HK$55.1 million and EPS of HK$0.0028, while trailing twelve month figures show revenue of HK$89.3 million and EPS of HK$0.0449 loss alongside a net loss of HK$37.9 million. The company has seen recent half year revenue move from HK$70.9 million in 1H FY 2025 to HK$64.7 million in 2H FY 2025 and HK$55.1 million in 1H FY 2026, with EPS shifting from a HK$0.0092 loss to HK$0.0083...